Published in J Am Heart Assoc on February 22, 2013
Arrhythmia risk stratification of patients after myocardial infarction using personalized heart models. Nat Commun (2016) 1.62
Changes in Follow-Up Left Ventricular Ejection Fraction Associated With Outcomes in Primary Prevention Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Device Recipients. J Am Coll Cardiol (2015) 1.43
Risk stratification for sudden cardiac death: current status and challenges for the future. Eur Heart J (2014) 1.11
Repolarization Lability Measured by Spatial TT' Angle. Comput Cardiol (2010) (2014) 0.89
Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD). Circ Arrhythm Electrophysiol (2014) 0.85
Left Ventricular Dilatation Increases the Risk of Ventricular Arrhythmias in Patients With Reduced Systolic Function. J Am Heart Assoc (2015) 0.80
Serum amine-based metabolites and their association with outcomes in primary prevention implantable cardioverter-defibrillator patients. Europace (2015) 0.78
Clinical and serum-based markers are associated with death within 1 year of de novo implant in primary prevention ICD recipients. Heart Rhythm (2014) 0.76
Primary prevention implantable cardioverter-defibrillators in older racial and ethnic minority patients. Circ Arrhythm Electrophysiol (2014) 0.75
Clinical decision tool for CRT-P vs. CRT-D implantation: Findings from PROSE-ICD. PLoS One (2017) 0.75
Serum-Based Oxylipins Are Associated with Outcomes in Primary Prevention Implantable Cardioverter Defibrillator Patients. PLoS One (2016) 0.75
A feasibility study of arrhythmia risk prediction in patients with myocardial infarction and preserved ejection fraction. Europace (2016) 0.75
Predictors of mortality, LVAD implant, or heart transplant in primary prevention cardiac resynchronization therapy recipients: The HF-CRT score. Heart Rhythm (2015) 0.75
Searching for sudden death snps in calcium handling genes. J Am Heart Assoc (2013) 0.75
Associations between scar characteristics by cardiac magnetic resonance and changes in left ventricular ejection fraction in primary prevention defibrillator recipients. Heart Rhythm (2016) 0.75
Entropy of cardiac repolarization predicts ventricular arrhythmias and mortality in patients receiving an implantable cardioverter-defibrillator for primary prevention of sudden death. Europace (2016) 0.75
Quantifying left atrial structure and function using single-plane tissue-tracking cardiac magnetic resonance. Magn Reson Imaging (2017) 0.75
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med (2002) 27.55
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med (2005) 27.36
Sudden cardiac death. Circulation (1998) 9.41
Sudden cardiac death in the United States, 1989 to 1998. Circulation (2001) 7.92
Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med (2008) 5.13
Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol (2004) 4.44
A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol (2008) 3.58
Clinical classification of cardiac deaths. Circulation (1982) 2.93
Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death. Circ Cardiovasc Imaging (2012) 2.62
Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation (2001) 2.50
Microvolt T-wave alternans identifies patients with ischemic cardiomyopathy who benefit from implantable cardioverter-defibrillator therapy. J Am Coll Cardiol (2006) 2.34
Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol (2011) 2.31
The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention. J Am Coll Cardiol (2009) 2.22
Does microvolt T-wave alternans testing predict ventricular tachyarrhythmias in patients with ischemic cardiomyopathy and prophylactic defibrillators? The MASTER (Microvolt T Wave Alternans Testing for Risk Stratification of Post-Myocardial Infarction Patients) trial. J Am Coll Cardiol (2008) 2.18
Implantable cardioverter-defibrillator registry risk score models for acute procedural complications or death after implantable cardioverter-defibrillator implantation. Circulation (2011) 1.82
Pacemaker and ICD generator reliability: meta-analysis of device registries. JAMA (2006) 1.62
Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. JACC Cardiovasc Imaging (2009) 1.46
Early identification of risk factors for sudden cardiac death. Nat Rev Cardiol (2010) 1.27
Time for a change--a new approach to ICD replacement. N Engl J Med (2012) 1.16
Plasma biomarkers for prediction of sudden cardiac death: another piece of the risk stratification puzzle? Circ Arrhythm Electrophysiol (2012) 0.98
Noninvasive risk stratification for sudden death: signal-averaged electrocardiography, nonsustained ventricular tachycardia, heart rate variability, baroreflex sensitivity, and QRS duration. Prog Cardiovasc Dis (2008) 0.90
Pursuing the "Holy Grail". Circ Cardiovasc Imaging (2012) 0.81
The role of electrophysiology study in risk stratification of sudden cardiac death. Prog Cardiovasc Dis (2008) 0.80
Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med (2004) 17.79
Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation (2010) 13.28
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
Body-mass index and mortality in Korean men and women. N Engl J Med (2006) 7.50
A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med (2013) 5.52
Enough is enough: Stop wasting money on vitamin and mineral supplements. Ann Intern Med (2013) 5.28
Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation (2007) 5.09
2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation (2013) 5.02
Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock. Cell (2004) 3.98
Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation (2003) 3.97
Arsenic exposure and prevalence of type 2 diabetes in US adults. JAMA (2008) 3.83
Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ (2011) 3.69
2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 3.63
Rapid response systems: a systematic review. Crit Care Med (2007) 3.51
Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. Circulation (2006) 3.47
Electrocardiographic features of arrhythmogenic right ventricular dysplasia/cardiomyopathy according to disease severity: a need to broaden diagnostic criteria. Circulation (2004) 3.35
Random-effects meta-analysis of inconsistent effects: a time for change. Ann Intern Med (2014) 3.30
End-stage renal disease predicts complications in pacemaker and ICD implants. J Cardiovasc Electrophysiol (2011) 3.21
Lead exposure and cardiovascular disease--a systematic review. Environ Health Perspect (2006) 3.11
Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. Am J Epidemiol (2005) 3.10
The mitochondrial origin of postischemic arrhythmias. J Clin Invest (2005) 3.08
Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes. Diabetes Educ (2003) 3.05
Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol (2008) 2.99
Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study. J Cardiovasc Electrophysiol (2011) 2.98
Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) trial. Circulation (2013) 2.90
Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence. Am J Epidemiol (2005) 2.90
Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation (2004) 2.83
Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation (2005) 2.80
ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. Heart Rhythm (2008) 2.75
Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA (2010) 2.68
Cardiac magnetic resonance assessment of dyssynchrony and myocardial scar predicts function class improvement following cardiac resynchronization therapy. JACC Cardiovasc Imaging (2008) 2.64
Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death. Circ Cardiovasc Imaging (2012) 2.62
Genetic variations in nitric oxide synthase 1 adaptor protein are associated with sudden cardiac death in US white community-based populations. Circulation (2009) 2.55
Cadmium exposure and incident cardiovascular disease. Epidemiology (2013) 2.55
Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol (2013) 2.50
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol (2011) 2.48
Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiological evidence. Environ Health Perspect (2006) 2.44
Initial experience in the use of integrated electroanatomic mapping with three-dimensional MR/CT images to guide catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol (2006) 2.40
Vitamin-mineral supplementation and the progression of atherosclerosis: a meta-analysis of randomized controlled trials. Am J Clin Nutr (2006) 2.40
Acute termination of human atrial fibrillation by identification and catheter ablation of localized rotors and sources: first multicenter experience of focal impulse and rotor modulation (FIRM) ablation. J Cardiovasc Electrophysiol (2012) 2.40
Sex-steroid hormones and electrocardiographic QT-interval duration: findings from the third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol (2011) 2.38
Pulmonary vein anatomy in patients undergoing catheter ablation of atrial fibrillation: lessons learned by use of magnetic resonance imaging. Circulation (2003) 2.35
Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J (2011) 2.29
Electrocardiographic features of arrhythmogenic right ventricular dysplasia. Circulation (2009) 2.22
The future of fellowship training in clinical cardiac electrophysiology: Program directors' perspective 2008. Heart Rhythm (2009) 2.22
Benefit of primary prevention implantable cardioverter-defibrillators in the setting of chronic kidney disease: a decision model analysis. J Cardiovasc Electrophysiol (2008) 2.21
Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res (2004) 2.19
Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Cardiovasc Genet (2009) 2.19
Quality of life after acute respiratory distress syndrome: a meta-analysis. Intensive Care Med (2006) 2.13
Lead extraction in the contemporary setting: the LExICon study: an observational retrospective study of consecutive laser lead extractions. J Am Coll Cardiol (2010) 2.11
Post-transcriptional gene silencing of KChIP2 and Navbeta1 in neonatal rat cardiac myocytes reveals a functional association between Na and Ito currents. J Mol Cell Cardiol (2008) 2.09
Electrophysiological consequences of dyssynchronous heart failure and its restoration by resynchronization therapy. Circulation (2009) 2.09
Blood cadmium and lead and chronic kidney disease in US adults: a joint analysis. Am J Epidemiol (2009) 2.06
Long-term single procedure efficacy of catheter ablation of atrial fibrillation. J Interv Card Electrophysiol (2006) 2.05
Referral, enrollment, and delivery of cardiac rehabilitation/secondary prevention programs at clinical centers and beyond: a presidential advisory from the American Heart Association. Circulation (2011) 2.05
Associations of blood lead with estimated glomerular filtration rate using MDRD, CKD-EPI and serum cystatin C-based equations. Nephrol Dial Transplant (2011) 2.04
Clinical competency statement: Training pathways for implantation of cardioverter defibrillators and cardiac resynchronization devices. Heart Rhythm (2004) 2.01
Influence of serum selenium concentrations on hypertension: the Lipid Analytic Cologne cross-sectional study. J Hypertens (2012) 2.00
Adenosine facilitates dormant conduction across cavotricuspid isthmus following catheter ablation. Heart Rhythm (2012) 2.00
Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med (2003) 1.98
Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci (2007) 1.97
Cardiac sarcoidosis: contemporary review. J Cardiovasc Electrophysiol (2014) 1.97
Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol (2010) 1.97
Serum selenium and diabetes in U.S. adults. Diabetes Care (2007) 1.96
Downloadable algorithm to reduce inappropriate shocks caused by fractures of implantable cardioverter-defibrillator leads. Circulation (2008) 1.96
Gaps in the ablation line as a potential cause of recovery from electrical isolation and their visualization using MRI. Circ Arrhythm Electrophysiol (2011) 1.95
Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure. Am J Physiol Heart Circ Physiol (2007) 1.94
Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care (2004) 1.90
Na+ channel regulation by Ca2+/calmodulin and Ca2+/calmodulin-dependent protein kinase II in guinea-pig ventricular myocytes. Cardiovasc Res (2009) 1.88
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 1.87